摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(-)-2'-deoxy-3'-oxa-4'-thio-5-fluorocytidine

中文名称
——
中文别名
——
英文名称
(-)-2'-deoxy-3'-oxa-4'-thio-5-fluorocytidine
英文别名
4-amino-5-fluoro-1-[(2R,4R)-2-(hydroxymethyl)-1,3-oxathiolan-4-yl]pyrimidin-2-one
(-)-2'-deoxy-3'-oxa-4'-thio-5-fluorocytidine化学式
CAS
——
化学式
C8H10FN3O3S
mdl
——
分子量
247.25
InChiKey
PANPMNGUWWTDHB-PHDIDXHHSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -0.9
  • 重原子数:
    16
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    113
  • 氢给体数:
    2
  • 氢受体数:
    5

反应信息

点击查看最新优质反应信息

文献信息

  • Substituted 1,3-oxathiolanes with antiviral properties
    申请人:BioChem Pharma, Inc.
    公开号:US06369066B1
    公开(公告)日:2002-04-09
    This invention relates to single enantiomers of novel cis-substituted 1,3-oxathiolanes, of the formula (I): wherein; R1 is hydrogen, and R2 is cytosine or 5-fluorocytosine; and pharmaceutically acceptable salts and esters thereof. This invention also relates to pharmaceutical compositions containing them and to the use of these compounds as antiviral agents, particularly in combination therapy.
    这项发明涉及一种新型顺式取代的单对映体1,3-噁环己烷化学式为(I):其中;R1为氢,R2为胞嘧啶或5-胞嘧啶;以及其药学上可接受的盐和酯。这项发明还涉及含有它们的药物组合物,以及将这些化合物用作抗病毒剂,特别是在联合疗法中的用途。
  • [EN] SUBSTITUTED 1,3-OXATHIOLANES WITH ANTIVIRAL PROPERTIES<br/>[FR] 1,3-OXATHIOLANES SUBSTITUEES A PROPRIETES ANTIVIRALES
    申请人:BIOCHEM PHARMA INC.
    公开号:WO1995029176A1
    公开(公告)日:1995-11-02
    (EN) This invention relates to single enantiomers of novel $i(cis)-substituted 1,3-oxathiolanes, of formula (I) wherein R1 is hydrogen, and R2 is cytosine or 5-fluorocytosine, and pharmaceutically acceptable salts and esters thereof. This invention also relates to pharmaceutical compositions containing them and to the use of these compounds as antiviral agents, particularly in combination therapy.(FR) L'invention concerne des énantiomères individuels propres à de nouveaux 1,3-oxathiolanes substitués en $i(cis) de formule (I) dans laquelle R1 représente hydrogène, et R2 cytosine ou 5-fluorocytosine, ainsi que leurs sels et esters acceptables sur le plan pharmacologique. Elle concerne aussi des compositions pharmaceutiques les contenant et l'utilisation de ces composés comme agents antiviraux, notamment dans des thérapies combinées.
    这项发明涉及一种新型$ i(cis) $取代的单对映体1,3-氧杂环烷,化学式为(I),其中R1为氢,R2为胞嘧啶或5-胞嘧啶,以及其药学上可接受的盐和酯。该发明还涉及含有它们的制药组合物以及将这些化合物用作抗病毒剂,特别是在联合治疗中的用途。
  • Modulators of DUX4 for regulation of muscle function
    申请人:GENEA BIOCELLS USA (HOLDINGS), INC.
    公开号:US10933068B2
    公开(公告)日:2021-03-02
    Disclosed herein are methods and compositions for the treatment of facioscapulohumeral muscular dystrophy and other muscle diseases or disorders. In some cases, the methods and compositions involve the use of methyltransferase inhibitors to inhibit or repress DUX4 expression in muscle cells. Further disclosed herein are methods and cell based assays for screening compounds for the treatment of facioscapulohumeral muscular dystrophy and other muscle diseases.
    本文公开了治疗面肱骨肌营养不良症和其他肌肉疾病或紊乱的方法和组合物。在某些情况下,这些方法和组合物涉及使用甲基转移酶抑制剂来抑制或抑制肌肉细胞中 DUX4 的表达。本文进一步公开了用于筛选治疗面阔肌营养不良症和其他肌肉疾病的化合物的方法和基于细胞的检测方法。
  • Structure-Activity Relationships Among a New Class of Antiviral Heterosubstituted 2',3'-Dideoxynucleoside Analogues
    作者:Tarek Mansour、Haolun Jin、Wei Wang、Dilip Dixit、Colleen Evans、H. L. Allan Tse、Bernard Belleau、John Gillard、Elizabeth Hooker、Claire Ashman、Nick Cammack、Horacio Salomon、Antonietta Belmonte、Mark Wainberg
    DOI:10.1080/15257779508012439
    日期:1995.5.1
    3'-Oxa-4'-thiocytidine nucleoside analogues 14-17 were prepared from oxathiolanes 10 and 11, and evaluated for activity against HIV-1 and HBV in vitro. The nucleoside analogues were found to possess potent activities against HIV-1 in a panel of cell lines. Compound 16 is moderately active against HBV in 2.2.15 cells.
  • SUBSTITUTED 1,3-OXATHIOLANES WITH ANTIVIRAL PROPERTIES
    申请人:BIOCHEM PHARMA INC.
    公开号:EP0756595A1
    公开(公告)日:1997-02-05
查看更多